CD4 and Osteoblastoma: Since RUNX2 is under control of distinct promoters, which give rise to two distinct RUNX2 variants (Stock and Otto, 2005; Mevel et al., 2019), we selected the CD4-expressed RUNX2 variant for both ectopic expression and subsequent RUNX2 KD experiments; proximal promoter variant1 was expressed in gut-derived primary T cells from CD patients, while a human osteoblastoma cell line Saos2 barely expressed this variant but highly expressed distal promoter variant2 (Fig. S4 C).